covid-19, variants of concern, Omicron, Delta, vaccination, SARS-CoV-2
COVID-19, vaccination, Phase IV trial, Pfizer-BioNTech, Oxford/AstraZeneca, BNT162b2, ChAdOx1 nCoV-19, mRNA-1273